Compass Therapeutics (CMPX) EBT (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of EBT data on file, last reported at -$53.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 219.91% year-over-year to -$53.2 million; the trailing twelve-month figure through Mar 2026 stood at -$126.8 million (down 111.23% YoY), and the FY2025 full-year result was -$152.0 million, down 31.06% from the prior year.
• EBT slipped to -$53.2 million in Q1 2026, from -$18.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$7.2 million in Q1 2022 to a low of -$53.2 million in Q1 2026.
• A 5-year average of -$16.4 million and a median of -$13.1 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT grew 16.79% in 2023 and sank 219.91% in 2026, its largest moves.
• Tracing CMPX's EBT over 5 years: stood at -$11.6 million in 2022, then retreated by 15.71% to -$13.4 million in 2023, then slipped by 25.61% to -$16.8 million in 2024, then retreated by 7.32% to -$18.1 million in 2025, then sank by 194.24% to -$53.2 million in 2026.
• Business Quant data shows CMPX's EBT at -$53.2 million in Q1 2026, -$18.1 million in Q4 2025, and -$27.4 million in Q3 2025.